18F‐Fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Issue 6 (11th December 2012)

• Record Type: Journal Article
• Authors: Al‐Ibraheem, Akram; Buck, Andreas K.; Benz, Matthias R.; Rudert, Maximilian; Beer, Ambros J.; Mansour, Asem; Pomykala, Kelsey L.; Haller, Bernhard; Juenger, Hendrik; Scheidhauer, Klemens; Schwaiger, Markus; Herrmann, Ken
• Is Part Of: Cancer. Volume 119:Issue 6(2013)
• Page Start: 1227
• Page End: 1234
• Publication Date: 2012-12-11
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.27866
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="abs1-1" sec-type="section"> <title>BACKGROUND:</title> <p>The clinical utility of modern hybrid imaging modalities for detecting recurrent bone or soft tissue sarcoma remains to be determined. In this report, the authors present a clinical study on the diagnostic accuracy and incremental value of integrated <sup>18</sup>F‐fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F‐FDG PET/CT) in patients with a history of sarcoma who have clinically suspected disease recurrence.</p> </sec> <sec id="abs1-2" sec-type="section"> <title>METHODS:</title> <p>Forty‐three patients who had a history of bone or soft tissue sarcoma and had documented complete remission underwent <sup>18</sup>F‐FDG PET/CT. Image analysis was performed independently for <sup>18</sup>F‐FDG PET (n = 43) and for contrast‐enhanced spiral CT (CE‐CT) (n = 30) by 2 separate readers, whereas combined <sup>18</sup>F‐FDG PET/CT (n = 43) images were analyzed in consensus by both readers. Imaging findings were rated on a 5‐point scale and finally were reported as malignant, benign, or equivocal. Imaging findings were validated either by histopathology (n = 24) or by clinical follow‐up (n = 19).</p> </sec> <sec id="abs1-3" sec-type="section"> <title>RESULTS:</title> <p> <sup>18</sup>F‐FDG PET/CT had greater sensitivity and specificity compared with CE‐CT alone (94% and 92% vs 78% and 67%, respectively), resulting in significantly greater accuracy (93% vs 73%; <italic>P</italic> = .03). <sup>18</sup>F‐FDG PET/CT was particularly superior regarding detection of local recurrence or soft tissue lesions (sensitivity and specificity: 83% and 100% vs 50% and 100%, respectively) or bone metastases (100% and 100% vs 85% and 88%, respectively).</p> </sec> <sec id="abs1-4" sec-type="section"> <title>CONCLUSIONS:</title> <p> <sup>18</sup>F‐FDG PET/CT had greater diagnostic accuracy in the detection of recurrent bone or soft tissue sarcoma compared with CE‐CT alone. The detection of local recurrence was the most evident advantage of <sup>18</sup>F‐FDG PET/CT over CE‐CT. Cancer 2013. © 2012 American Cancer Society.</p> </sec> </abstract>